|
We asked 40 leaders, What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
| Improves the quality and number of innovative drugs available to patients |
18% |
| Restricts innovation and the development of new drugs |
54% |
| Has no impact on drug development |
7% |
| Don’t Know |
21% |
 |
|
|
|
|
|
|
|
27 May, 2014
|
|
|
Rebuilding European Pharma’s Competitive Agenda
Partly because of the tougher conditions they face, and partly because shifts in ownership and in corporate strategy, EFPIA and EGA they have started to work together much more closely in Europe. Reflector reports...Read more |
Pharma MBAs — From Mini Courses to the Full Monty
Over the past decade there has been a marked increase in the variety of specialist pharma MBA courses on offer. These courses last from one week in the case of most mini MBAs, up to a year’s full-time study or equivalent. Accordingly, the depth of learning provided by these different types of course varies enormously, writes John Ansell ... Read more
|
The Future of Cancer Care?
In the next 3–5 years, innovation in cancer care will not be about the technology or some great pharmaceutical breakthrough. It will really be about changes in human behavior, writes Jim Austin ... Read more
|
The European Medicine Agency’s Transparency Dilemma
The European Medicines Agency thought it might at last be back on the road to salvation when Guido Rasi swept into town in 2011 and started ordering greater transparency. But instead the EMA finds itself, yet again, on the road to hell. Peter O’Donnell reports ... Read more
|
UK Patient Group Sets Out Orphan Drugs Charter
There has been a lot of concern about the decision to give NICE the responsibility to look at “highly specialized technologies” (HSTs). Now a new Patient Charter has been launched to act as a sense check on how NICE applies their interim guidance on appraising HSTs. Leela Barham reports ... Read more
|
|
| Oracle |
 Instantly Access Clinical Payment Data and Reduce Trial Costs by Automating and Centralizing Investigator Payments with Oracle Health Sciences InForm and Greenphire
Watch a webcast that highlights how the integration of Oracle Health Sciences InForm EDC System and Greenphire's eClinicalGPS payment
system allows biopharmaceutical and healthcare companies increased access to clinical financial data & metrics while reducing trial costs with easily configurable and automated site payments.  Click here to view the webcast |
|
|
|
|
|
|
|
|
